WIF1 Fusion

CI-VAR-00001355Explore in graph →CIViC 4344

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
IDH-wildtype Glioblastoma1unmapped disease
EGFR::WIF1 Fusion	Bevacizumab	Predictive	B	Supports Sensitivity Response	2	submitted	EID11104 EGFR::WIF1 was identified by RNA-seq in a tumor sample derived from 1/78 recurrent glioblastoma patients in the BELOB clinical trial. The IDH-wildtype GBM tumor from this 59yo female patient belonged … (full text at CIViC) PMID 26762204 · Erdem-Eraslan et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.